Handel Annexon, Inc. - ANNX CFD
Føj til favorit- Opsummering
- Historisk Data
- Begivenheder
- Resultatopgørelse
- Saldo
- Cash flow
- Ejerskab
Handelsbetingelser
| Spænd | 0.06 | ||||||||
|
Long position, gebyr natten over
Long position overnight fee
Gå til platform | -0.025457% | ||||||||
|
Short position, gebyr natten over
Short position overnight fee
Gå til platform | 0.003235% | ||||||||
| Gebyr natten over, tid | 21:00 (UTC) | ||||||||
| Min. handlet mængde | 1 | ||||||||
| Valuta | USD | ||||||||
| Margen | 20% | ||||||||
| Aktiebørs | United States of America | ||||||||
| Kommission på handel | 0% |
*Information provided by Capital.com
Annexon Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Nøglestatistikker
| Tidligere luk* | 3.11 |
| Åben* | 3.15 |
| 1-Års Ændring* | -6.25% |
| Dagens Spænd* | 2.98 - 3.2 |
| 52-Ugers Spænd | 2.07-7.65 |
| Gennemsnitlig Volumen (10 dage) | 2.55M |
| Gennemsnitlig Volumen (3 måneder) | 16.64M |
| Market Cap | 158.19M |
| P/E-forhold | -100.00K |
| Udestående aktier | 53.08M |
| Omsætning | N/A |
| EPS | -2.47 |
| Dividend (Udbytte %) | N/A |
| Beta | -100.00K |
| Næste indtjeningsopgørelse | Aug 7, 2023 |
Al data kommer fra Refinitiv, med undtagelse af data markeret med en asterisk, som er *data fra Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Luk | Change | Change (%) | Åben | High | Low |
|---|---|---|---|---|---|---|
| Jun 6, 2023 | 3.20 | 0.14 | 4.58% | 3.06 | 3.22 | 2.98 |
| Jun 5, 2023 | 3.11 | 0.15 | 5.07% | 2.96 | 3.23 | 2.87 |
| Jun 1, 2023 | 3.14 | 0.22 | 7.53% | 2.92 | 3.20 | 2.81 |
| May 31, 2023 | 2.97 | 0.14 | 4.95% | 2.83 | 3.03 | 2.60 |
| May 30, 2023 | 2.71 | 0.02 | 0.74% | 2.69 | 2.95 | 2.48 |
| May 26, 2023 | 2.78 | 0.71 | 34.30% | 2.07 | 2.81 | 2.05 |
| May 25, 2023 | 2.06 | -0.36 | -14.88% | 2.42 | 2.44 | 2.04 |
| May 24, 2023 | 5.15 | -0.33 | -6.02% | 5.48 | 5.63 | 5.05 |
| May 23, 2023 | 5.57 | -0.22 | -3.80% | 5.79 | 6.09 | 5.56 |
| May 22, 2023 | 5.94 | 0.27 | 4.76% | 5.67 | 6.04 | 5.66 |
| May 19, 2023 | 5.86 | 0.13 | 2.27% | 5.73 | 5.97 | 5.67 |
| May 18, 2023 | 5.76 | -0.47 | -7.54% | 6.23 | 6.61 | 5.72 |
| May 17, 2023 | 6.35 | 0.38 | 6.37% | 5.97 | 6.40 | 5.78 |
| May 16, 2023 | 6.00 | 0.06 | 1.01% | 5.94 | 6.15 | 5.77 |
| May 15, 2023 | 6.03 | 0.60 | 11.05% | 5.43 | 6.22 | 5.41 |
| May 12, 2023 | 5.44 | -0.02 | -0.37% | 5.46 | 5.59 | 5.41 |
| May 11, 2023 | 5.45 | -0.15 | -2.68% | 5.60 | 5.67 | 5.38 |
| May 10, 2023 | 5.59 | 0.20 | 3.71% | 5.39 | 5.79 | 5.35 |
| May 9, 2023 | 5.43 | 0.33 | 6.47% | 5.10 | 5.48 | 4.90 |
| May 8, 2023 | 5.21 | 0.17 | 3.37% | 5.04 | 5.26 | 5.03 |
Annexon, Inc. Events
| Tid (UTC) (UTC) | Land | Begivenhed |
|---|---|---|
| Thursday, June 8, 2023 | ||
| Tid (UTC) (UTC) 13:30 | Land US
| Begivenhed Annexon Inc Annual Shareholders Meeting Annexon Inc Annual Shareholders MeetingForecast -Previous - |
| Friday, June 9, 2023 | ||
| Tid (UTC) (UTC) 16:00 | Land US
| Begivenhed Annexon Inc Annual Shareholders Meeting Annexon Inc Annual Shareholders MeetingForecast -Previous - |
| Monday, August 7, 2023 | ||
| Tid (UTC) (UTC) 10:59 | Land US
| Begivenhed Q2 2023 Annexon Inc Earnings Release Q2 2023 Annexon Inc Earnings ReleaseForecast -Previous - |
| Wednesday, November 1, 2023 | ||
| Tid (UTC) (UTC) 12:30 | Land US
| Begivenhed Q3 2023 Annexon Inc Earnings Release Q3 2023 Annexon Inc Earnings ReleaseForecast -Previous - |
- Årlig
- Pr kvartal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total omsætning | 0 | 0 | 0 | 0 | 0 |
| Totale Driftsudgifter | 145.599 | 130.713 | 63.469 | 32.328 | 19.112 |
| Salgs/Generelle/Admin. Udgifter, Total | 33.098 | 30.647 | 14.198 | 7.994 | 3.619 |
| Forskning & Udvikling | 112.501 | 100.066 | 49.271 | 24.524 | 15.528 |
| Driftsindtægter | -145.599 | -130.713 | -63.469 | -32.328 | -19.112 |
| Andre, Netto | 3.652 | 0.385 | 0.048 | -4.865 | 0.769 |
| Netto Indkomst Før Skat | -141.947 | -130.323 | -63.412 | -37.179 | -18.303 |
| Netto Indkomst Efter Skat | -141.947 | -130.323 | -63.412 | -37.183 | -18.304 |
| Netto Indkomst Før Ekstra Ting | -141.947 | -130.323 | -63.412 | -37.183 | -18.304 |
| Totale Ekstraordinære Ting | |||||
| Netto Indkomst | -141.947 | -130.323 | -63.412 | -37.183 | -18.304 |
| Total Adjustments to Net Income | 0 | -6.924 | -1.095 | -0.176 | |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -141.947 | -130.323 | -70.336 | -38.278 | -18.48 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -141.947 | -130.323 | -70.336 | -38.278 | -18.48 |
| Fortyndet Netto Indkomst | -141.947 | -130.323 | -70.336 | -38.278 | -18.48 |
| Fortyndet Vægtet Gennemsnit Aktier | 54.6736 | 38.3163 | 16.9624 | 187.289 | 187.289 |
| Fortyndet EPS Uden Ekstraordinære Ting | -2.59626 | -3.40124 | -4.14658 | -0.20438 | -0.09867 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
| Fortyndet Normaliseret EPS | -2.59626 | -3.40124 | -4.14658 | -0.20504 | -0.09879 |
| Usædvanlig Udgift (Indkomst) | -0.19 | -0.035 | |||
| Renteindkomst (Udgift), Netto Ikke-Drift | 0.005 | 0.009 | 0.014 | 0.04 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total omsætning | 0 | 0 | 0 | 0 | 0 |
| Totale Driftsudgifter | 41.242 | 36.695 | 36.069 | 37.409 | 35.426 |
| Salgs/Generelle/Admin. Udgifter, Total | 8.897 | 8.16 | 8.207 | 8.303 | 8.428 |
| Forskning & Udvikling | 32.345 | 28.535 | 27.862 | 29.106 | 26.998 |
| Driftsindtægter | -41.242 | -36.695 | -36.069 | -37.409 | -35.426 |
| Andre, Netto | 2.566 | 2.312 | 1.015 | 0.272 | 0.053 |
| Netto Indkomst Før Skat | -38.676 | -34.383 | -35.054 | -37.137 | -35.373 |
| Netto Indkomst Efter Skat | -38.676 | -34.383 | -35.054 | -37.137 | -35.373 |
| Netto Indkomst Før Ekstra Ting | -38.676 | -34.383 | -35.054 | -37.137 | -35.373 |
| Netto Indkomst | -38.676 | -34.383 | -35.054 | -37.137 | -35.373 |
| Total Adjustments to Net Income | |||||
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -38.676 | -34.383 | -35.054 | -37.137 | -35.373 |
| Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -38.676 | -34.383 | -35.054 | -37.137 | -35.373 |
| Fortyndet Netto Indkomst | -38.676 | -34.383 | -35.054 | -37.137 | -35.373 |
| Fortyndet Vægtet Gennemsnit Aktier | 73.8556 | 72.563 | 68.6529 | 38.5844 | 38.5634 |
| Fortyndet EPS Uden Ekstraordinære Ting | -0.52367 | -0.47384 | -0.5106 | -0.96249 | -0.91727 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Fortyndet Normaliseret EPS | -0.52367 | -0.47384 | -0.5106 | -0.96249 | -0.91727 |
- Årlig
- Pr kvartal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Totale Nuværende Aktiver | 248.098 | 247.693 | 354.011 | 45.406 | 45.706 |
| Likvider og Kortsigtede Investeringer | 242.657 | 242.715 | 351.206 | 43.931 | 44.175 |
| Likvider & Lignende | 140.02 | 74.843 | 268.565 | 43.931 | 44.175 |
| Prepaid Expenses | 5.238 | 4.515 | 2.802 | 1.396 | 1.306 |
| Total Assets | 285.096 | 287.04 | 355.946 | 49.898 | 48.149 |
| Property/Plant/Equipment, Total - Net | 35.966 | 38.181 | 1.935 | 2.138 | 2.345 |
| Property/Plant/Equipment, Total - Gross | 38.849 | 38.97 | 3.906 | 3.442 | 3.156 |
| Accumulated Depreciation, Total | -2.883 | -0.789 | -1.971 | -1.304 | -0.811 |
| Other Long Term Assets, Total | 1.032 | 1.166 | 0 | 2.354 | 0.098 |
| Total Current Liabilities | 22.36 | 21.744 | 10.622 | 4.931 | 3.326 |
| Accounts Payable | 7.416 | 11.153 | 3.734 | 2.371 | 1.271 |
| Accrued Expenses | 14.764 | 10.452 | 6.497 | 2.194 | 1.713 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0.18 | 0.139 | 0.391 | 0.366 | 0.342 |
| Total Liabilities | 53.902 | 55.131 | 11.668 | 6.368 | 5.129 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 31.542 | 33.387 | 1.046 | 1.437 | 1.803 |
| Total Equity | 231.194 | 231.909 | 344.278 | 43.53 | 43.02 |
| Redeemable Preferred Stock | 0 | 0 | 143.984 | 107.222 | |
| Common Stock | 0.048 | 0.039 | 0.038 | 0.004 | 0.004 |
| Additional Paid-In Capital | 669.78 | 528.365 | 510.309 | 2.202 | 1.257 |
| Retained Earnings (Accumulated Deficit) | -438.262 | -296.315 | -165.992 | -102.58 | -65.397 |
| Other Equity, Total | -0.372 | -0.18 | -0.077 | -0.08 | -0.066 |
| Total Liabilities & Shareholders’ Equity | 285.096 | 287.04 | 355.946 | 49.898 | 48.149 |
| Total Common Shares Outstanding | 47.723 | 38.5608 | 38.1576 | 187.289 | 187.289 |
| Totale Tilgodehavender, Netto | 0 | 0.003 | 0.079 | 0.225 | |
| Kortsigtede Investeringer | 102.637 | 167.872 | 82.641 | ||
| Other Current Assets, Total | 0.203 | 0.463 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Totale Nuværende Aktiver | 232.536 | 248.098 | 274.777 | 181.372 | 211.254 |
| Likvider og Kortsigtede Investeringer | 228.165 | 242.657 | 269.519 | 177.594 | 206.659 |
| Likvider & Lignende | 144.12 | 140.02 | 210.658 | 104.614 | 112.828 |
| Kortsigtede Investeringer | 84.045 | 102.637 | 58.861 | 72.98 | 93.831 |
| Totale Tilgodehavender, Netto | |||||
| Prepaid Expenses | 4.206 | 5.238 | 5.201 | 3.741 | 4.461 |
| Total Assets | 268.778 | 285.096 | 312.722 | 220.704 | 250.569 |
| Property/Plant/Equipment, Total - Net | 35.198 | 35.966 | 36.709 | 37.282 | 37.908 |
| Accumulated Depreciation, Total | -3.419 | -2.883 | -2.353 | -1.834 | -1.295 |
| Other Long Term Assets, Total | 1.044 | 1.032 | 1.236 | 2.05 | 1.407 |
| Total Current Liabilities | 22.941 | 22.36 | 20.22 | 20.254 | 17.053 |
| Accounts Payable | 10.346 | 7.416 | 6.921 | 10.301 | 9.378 |
| Accrued Expenses | 12.211 | 14.764 | 13.129 | 9.789 | 7.486 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0.384 | 0.18 | 0.17 | 0.164 | 0.189 |
| Total Liabilities | 53.917 | 53.902 | 52.12 | 52.66 | 49.955 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 30.976 | 31.542 | 31.9 | 32.406 | 32.902 |
| Total Equity | 214.861 | 231.194 | 260.602 | 168.044 | 200.614 |
| Common Stock | 0.053 | 0.048 | 0.048 | 0.039 | 0.039 |
| Additional Paid-In Capital | 691.963 | 669.78 | 664.839 | 537.269 | 532.636 |
| Retained Earnings (Accumulated Deficit) | -476.938 | -438.262 | -403.879 | -368.825 | -331.688 |
| Other Equity, Total | -0.217 | -0.372 | -0.406 | -0.439 | -0.373 |
| Total Liabilities & Shareholders’ Equity | 268.778 | 285.096 | 312.722 | 220.704 | 250.569 |
| Total Common Shares Outstanding | 53.0807 | 47.723 | 47.6265 | 38.6039 | 38.5636 |
| Property/Plant/Equipment, Total - Gross | 38.617 | 38.849 | 39.062 | 39.116 | 39.203 |
| Other Current Assets, Total | 0.165 | 0.203 | 0.057 | 0.037 | 0.134 |
| Redeemable Preferred Stock |
- Årlig
- Pr kvartal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Netto indkomst/Startlinje | -141.947 | -130.323 | -63.412 | -37.183 | -18.304 |
| Likvider Fra Driftsaktiviteter | -116.309 | -106.11 | -53.087 | -28.358 | -17.19 |
| Likvider Fra Driftsaktiviteter | 2.106 | 2.141 | 0.667 | 0.493 | 0.488 |
| Ikke-Likvide Ting | 19.794 | 18.788 | 4.941 | 7.707 | 0.148 |
| Cash Taxes Paid | 0 | 0.002 | 0.001 | ||
| Ændringer i Driftskapital | 3.738 | 3.284 | 4.717 | 0.625 | 0.478 |
| Likvider fra Investeringsaktiviteter | 58.443 | -88.236 | -83.164 | -0.267 | -0.017 |
| Kapitaludgifter | -6.526 | -1.654 | -0.464 | -0.267 | -0.017 |
| Likvider fra Financieringsaktiviteter | 122.908 | 1.795 | 360.876 | 28.395 | 58.456 |
| Udstedelse (Pensionering) af Aktier, Netto | 130.896 | 1.795 | 363.85 | 30 | 58.456 |
| Udenlandsk Børs Effekter | 0.001 | -0.005 | 0.009 | -0.014 | -0.04 |
| Netto Ændring i Likviditet | 65.043 | -192.556 | 224.634 | -0.244 | 41.209 |
| Financiering af Cash-Flow-Ting | -7.988 | 0 | -2.974 | -1.605 | 0 |
| Andre Investerings-Cash-Flow-Ting, Total | 64.969 | -86.582 | -82.7 | ||
| Udstedelse (Pensionering) af Gæld, Netto | 0 | 0 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -38.676 | -141.947 | -107.564 | -72.51 | -35.373 |
| Cash From Operating Activities | -32.993 | -116.309 | -89.17 | -58.452 | -30.288 |
| Cash From Operating Activities | 0.536 | 2.106 | 1.576 | 1.058 | 0.518 |
| Non-Cash Items | 3.969 | 19.794 | 14.89 | 9.842 | 4.862 |
| Changes in Working Capital | 1.178 | 3.738 | 1.928 | 3.158 | -0.295 |
| Cash From Investing Activities | 19.517 | 58.443 | 102.058 | 87.96 | 68.251 |
| Capital Expenditures | -0.137 | -6.526 | -6.244 | -6.075 | -5.214 |
| Other Investing Cash Flow Items, Total | 19.654 | 64.969 | 108.302 | 94.035 | 73.465 |
| Cash From Financing Activities | 17.581 | 122.908 | 122.8 | 0.132 | 0.019 |
| Financing Cash Flow Items | -7.988 | -7.853 | |||
| Issuance (Retirement) of Stock, Net | 17.581 | 130.896 | 130.653 | 0.132 | 0.019 |
| Foreign Exchange Effects | -0.005 | 0.001 | -0.007 | -0.003 | 0.003 |
| Net Change in Cash | 4.1 | 65.043 | 135.681 | 29.637 | 37.985 |
| Issuance (Retirement) of Debt, Net |
| Investornavn | Investortype | Procent udestående | Aktiebeholdning | Aktieændring | Beholdningsdato | IOmsætningsscore |
|---|---|---|---|---|---|---|
| Satter Management Co., L.P. | Private Equity | 13.2922 | 7056024 | 0 | 2023-03-31 | MED |
| Bain Capital Life Sciences Investors, LLC | Investment Advisor | 10.7413 | 5701926 | 815310 | 2023-05-25 | LOW |
| Adage Capital Management, L.P. | Hedge Fund | 6.6875 | 3549975 | 0 | 2023-03-31 | MED |
| Redmile Group, LLC | Investment Advisor/Hedge Fund | 6.5993 | 3503190 | 0 | 2023-03-31 | LOW |
| VR Adviser, LLC | Venture Capital | 6.066 | 3220050 | 0 | 2023-03-31 | MED |
| Federated Hermes Global Investment Management Corp. | Investment Advisor/Hedge Fund | 5.7603 | 3057800 | 0 | 2023-03-31 | LOW |
| Citadel Advisors LLC | Hedge Fund | 4.5459 | 2413117 | -87190 | 2023-03-31 | HIGH |
| Eventide Asset Management, LLC | Investment Advisor | 3.5175 | 1867250 | -1759258 | 2023-03-31 | MED |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.9575 | 1569971 | 21100 | 2023-03-31 | LOW |
| GMT Capital Corp. | Hedge Fund | 2.6537 | 1408697 | 1408697 | 2023-03-31 | LOW |
| Millennium Management LLC | Hedge Fund | 2.5702 | 1364343 | 837812 | 2023-03-31 | HIGH |
| Cormorant Asset Management, LP | Hedge Fund | 2.3548 | 1250000 | 1250000 | 2023-03-31 | LOW |
| Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 2.3222 | 1232713 | 0 | 2023-03-31 | LOW |
| Octagon Capital Advisors LP | Hedge Fund | 2.2417 | 1190000 | 1190000 | 2023-03-31 | MED |
| Driehaus Capital Management, LLC | Investment Advisor/Hedge Fund | 2.0552 | 1090986 | -200586 | 2023-03-31 | HIGH |
| Invus Public Equities Advisors, LLC | Investment Advisor | 1.9183 | 1018303 | 1018303 | 2023-03-31 | LOW |
| Polar Capital LLP | Investment Advisor/Hedge Fund | 1.8838 | 1000000 | 1000000 | 2023-03-31 | LOW |
| Soleus Capital Management, L.P. | Hedge Fund | 1.7244 | 915400 | 915400 | 2023-03-31 | HIGH |
| Novartis AG | Corporation | 1.7157 | 910747 | -1196497 | 2021-12-31 | LOW |
| Clarus Ventures, LLC | Venture Capital | 1.7147 | 910211 | 0 | 2023-03-31 | MED |
Hvorfor vælge Capital.com? Vores tal taler for sig selv.
Capital.com Group535K+
Handlende
87K+
Månedlkige, aktive klienter
$113M+
Månedlig investeringsvolumen
$64M+
Hævet hver måned
Handelslommeregner
Udregn dit hypotetiske P&L hvis du havde åbnet en CFD-handel på en given dato (vælg en dato) og lukket den på en anden dato (vælg en dato).
Handelskurtage
0
- 1:1
Gearing
1:1
- 20
- 100
- 500
- 1000
- 10000
Investering
Handelsstørrelse (Gearing x Investering):
Åben
Luk
Short Long
Annexon, Inc. Company profile
Om Annexon, Inc.
Annexon, Inc. er en biofarmaceutisk virksomhed i den kliniske fase, der udvikler en række behandlinger til patienter med klassiske komplementmedierede sygdomme i kroppen, hjernen og øjet. Selskabets produktkandidat, ANX005, er et fuldlængde monoklonalt antistof, der er formuleret til intravenøs administration ved autoimmune og neurodegenerative sygdomme. Produktkandidaten ANX007 er et antigenbindende fragment (Fab), der er formuleret til intravitreal administration til behandling af neurodegenerative øjensygdomme. Virksomheden er også ved at udvikle ANX009, som er en subkutan formulering af et Fab til behandling af systemiske autoimmune sygdomme. Virksomheden har afsluttet kliniske fase 1b sikkerheds- og doseringsforsøg for ANX005 og ANX007 i patienter med henholdsvis Guillain-Barre syndrom (GBS) og glaukom. Der gennemføres også kliniske forsøg med flere alvorlige autoimmune, neurodegenerative og oftalmiske sygdomme.
| Industry: | Biopharmaceuticals |
1400 Sierra Point Parkway
Bldg C Suite 200
BRISBANE
CALIFORNIA 94005
US
Resultatopgørelse
- Annual
- Quarterly
Folk ser også
Leder du stadig efter en mægler, du kan stole på?
Deltag sammen med 535.000+ handlende over hele verden, der valgte at handle hos Capital.com